Work

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.3035

Authors: A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram, A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige, P. Rajagopalan, M. Jeffers, D. Roth, R. L. Dubowy

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2474592988

Cites:

Cited by: 31

Related to: 10